Baicalein Inhibits TSLP-STAT5 Signaling for Allergic Disease Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for allergic diseases such as asthma and atopy, including bronchodilators and steroids, are only temporarily effective and fail to fundamentally control the diseases, often causing serious side effects, while existing therapeutic agents do not effectively target thymic stromal lymphopoietin (TSLP)-mediated signal transduction.
Innovation Solution
A pharmaceutical composition containing baicalein as an active ingredient, which regulates TSLP-mediated signal transduction by inhibiting intracellular phosphorylation of STATs and the binding of TSLP to TSLPR, potentially combined with other compounds like pelargonidin chloride, kaempferol, and synthetic oxazolo[4,5-c]quinolin-4(5H)-ones, to achieve synergistic effects in preventing or treating allergic diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If steroids and bronchodilators are used to treat allergic diseases, then symptoms are temporarily ameliorated, but the diseases cannot be fundamentally controlled and serious side effects occur
Solution Approach 1:
The patent extracts and targets the specific pathological mechanism (TSLP-mediated signal transduction) that drives allergic disease development, rather than using broad-spectrum anti-inflammatory agents. By isolating and inhibiting the specific TSLP pathway with baicalein, the treatment addresses the root cause while avoiding the non-specific side effects of steroids.
Solution Approach 2:
The patent changes the therapeutic parameter from non-specific anti-inflammatory suppression to specific TSLP pathway inhibition. This parameter change allows for targeted intervention at the molecular level (blocking TSLP-STAT5 signaling) while maintaining selectivity that reduces off-target side effects associated with conventional therapies.
2Reliability
If conventional therapeutic agents are used, then allergic symptoms are temporarily relieved, but the basic mechanism of allergic disease remains uncontrolled
Solution Approach 1:
The patent applies preliminary action by blocking TSLP-mediated signal transduction before Th2 cell differentiation and allergic inflammation fully develop. By inhibiting the upstream TSLP-STAT5 signaling pathway, the treatment prevents the cascade that leads to Th2 cell production and allergic responses, achieving fundamental control rather than temporary symptom relief.
Solution Approach 2:
The patent extracts the specific TSLP signaling pathway as the critical control point in allergic disease development. By focusing therapeutic intervention on this specific pathway rather than general inflammation, the treatment addresses the fundamental mechanism driving disease progression, enabling long-term control.
3Reliability
If TSLP-mediated signal transduction is targeted, then Th2 cell differentiation and activation are inhibited, but specific therapeutic agents with high selectivity are needed
Solution Approach 1:
The patent employs baicalein, a naturally occurring flavonoid compound with well-established safety and availability. This naturally occurring compound provides selective TSLP pathway inhibition without requiring complex synthetic molecules or biologics, achieving specific therapeutic effect with a simple, well-characterized compound that has favorable pharmacological properties.
Data Source
Figure 1
Figure 2
Figure 3~4
AI summary
The present invention relates to a pharmaceutical composition for preventing or treating allergic diseases such as asthma or atopy including baicalein as an active ingredient. Baicalein is capable of regulating thymic stromal lymphopoietin-mediated signal transduction. The pharmaceutical composition of the present invention can effectively suppress inflammatory responses of allergic or asthmatic diseases due to the presence of baicalein extracted from Scutellariae Radix that regulates TSLP-mediated intracellular signal transduction to inhibit intracellular phosphorylation of STAT5 and inhibit the binding of TSLP to TSLPR. In addition, the pharmaceutical composition of the present invention may further include one or more compounds having synergistic effects with baicalein. In this case, the pharmaceutical composition can more effectively suppress inflammatory responses of allergic diseases such as asthma or atopy.